Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE versus ENDOMETRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE versus ENDOMETRIN.
DROSPIRENONE vs ENDOMETRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
3 mg orally once daily.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
None Documented
None Documented
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Category C
Category C
Progestin
Progestin